Objective: The paper compared the utilization characteristics and trends of the high-value drugs between hospital outpatients (in-hospital) and retail pharmacies (out-of-hospital) under the “dual-channel” policy, and empirically analyzed the factors influencing patients' out-of-hospital medication behavior of high-value drugs at the individual level. Methods: We collected medical insurance reimbursement records of all insured patients in Weihai City, Shandong Province from 2019 to 2023 and relevant policy documents. Patients who had utilized and reimbursed the high-value drugs within the five years were selected as study samples. Descriptive statistical analysis was used to compare the differences in the number of patients, visits, and costs between the two channels (in-hospital and out-of-hospital) and across the five civil years. The Heckman sample selection model was employed to quantify hospital medication behavior from two aspects: the probability of out-of-hospital drug procurement and the proportion of out-of-hospital medication, and identify the influencing factors of out-of-hospital medication behavior from the dimensions of individual characteristics, disease characteristics, and treatment characteristics. Results: From 2019 to 2023, the average annual growth of the number of patients, visits, and costs for high-value drugs in Weihai City was 47.67%, 78.72%, and 24.89%, in which out-of-hospital channel increased by 81.95%, 135.77%, and 63.57% and the corresponding proportion reached 87.41%, 88.60%, and 88.05% by 2023. The results of Heckman model showed that compared to 2019, the out-of-hospital medication behavior for high-value drugs became more prominent from 2020 to 2023 (P<0.01). The probability of out-of-hospital drug procurement has significantly increased by 82.5%, 149.5%, 179.7%, and 169.9% in the past four years. Conclusions: The “dual-channel” policy promotes a rapid utilization increase of the high-value drugs, with a prominent trend of prescription outflow. Patients' out-of-hospital medication behavior has significant age trends, and is driven by factors such as cancer, heavy medication burden, long medication cycles, and low frequency of in-hospital medication.
Key words
“dual-channel” management /
high-value drugs /
retail pharmacy /
out-of-hospital medication behavior /
influencing factors
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024, 41(1): 9-13.
[2] 薛海宁,丁锦希.中国药品供应保障制度概论[M].北京:人民卫生出版社, 2024.
[3] 申远,杨莹,毛李宁,等.我国公立医疗机构国家谈判药品采购使用现状:基于13个地区的实证数据分析[J].中国卫生资源,2022,25(3):283-290.
[4] 毛李宁,文小桐,杨莹,等.国谈药品落地情况的宏观分析和研究——以湖北省为例[J].中国医疗保险, 2021(11):76-80.
[5] 杨赐然,王瑞,罗银,等.国谈药“双通道”管理政策设计的省际比较研究[J].中国卫生政策研究, 2023,16(4):25-31.
[6] 韩晓睿,丁锦希,李伟,等.国家谈判药品“双通道”的遴选标准与实施路径[J].世界临床药物, 2021,42(9):717-724.
[7] 张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15-18+23.
[8] 顾海,刁仁昌,石斌,等.国谈药“双通道”落地存在的问题及对策建议[J].中国医疗保险,2023(8): 59-65.
[9] 杨钰婷,胡婉慈,左根永.我国医疗保险国谈药品单独支付政策省际比较研究[J].中国卫生政策研究, 2024,17(1):24-29.
[10] 杨赐然,潘杰,毛宗福,等.国谈抗肿瘤药配备机构的空间可达性评价研究——以武汉市为例[J].中国卫生政策研究,2023,16(8): 55-64.
[11] 毛宗福,崔丹,文小桐.回眸“双通道”开通这一年[N].健康报,2022-05-23.
[12] 郑登滋,李玉水,陈纯,等.福建省推进国家谈判药品政策落地情况调研及实证分析——基于集中采购与特药药房数据[J].中国医疗保险, 2021(10):30-35.
[13] 曹庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究, 2022, 39(7): 53-56+59.
[14] 李婵,邹佳,徐焦,等.“双通道”模式下S省国谈药可获得性分析[J].中国医疗保险,2022(11): 54-59.
[15] 罗格莲,林瑾文,丁榕芳,等.福建省单列门诊统筹药品在政策实施前后使用情况对比分析[J].中国医疗保险,2022(7):88-92.
[16] 陈楠.山东省三市国家医保谈判药品政策实施现状、问题及对策研究[D].济南:山东大学, 2023.
[17] HECKMAN J J.Sample selection bias as a specification error[M].National Bureau of Economic Research,1977.
[18] 刘薇,武锋,苏日古嘎,等.门诊患者购药行为及其影响因素——以北京、郑州、广州市为例[J].中国卫生政策研究,2015,8(10): 46-50.
[19] 李前文,季国忠.癌症患者就医行为研究现状与思考[J].南京医科大学学报(社会科学版), 2022, 22(3):242-247.
[20] 胡佳惠,王臻.哈密地区居民用药行为影响因素分析[J].中国医院用药评价与分析,2017,17(1): 128-130+134.
[21] 中华人民共和国商务部市场运行和消费促进司.2021年药品流通行业运行统计分析报告[R].北京:2022.
[22] 龙南市人民政府.DRG/DIP实施后药品市场即将发生的3点变化[EB/OL].(2022-01-25)[2024-05-14].http://www.jxln.gov.cn/lnzf/ldxx/202201/958492d6040d434daecd5d540bf23a90.shtml.
[23] 第一药店财智.新形势下的药店破局之路——消费者健康需求洞察与市场机会[EB/OL].(2019-09-27)[2024-04-12].https://xueqiu.com/2495339241/133467656.
[24] CHEN C, FENG Z, FU Q, et al.Predictors of polypharmacy among elderly patients in china: the role of decision involvement, depression, and taking Chinese medicine behavior[J].Frontiers in pharmacology, 2021 (12): 745688.